Cancer Breakthrough with Spontaneous Remission by Jeffrey Dach MD

Cancer Breakthrough with lab mice spontaneous regression cancerSpontaneous Remission

by Jeffrey Dach MD

Injecting cancer into mice is a major activity at Wake Forest Medical School in North Carolina, keeping students busy with many publications over the years.  Injecting the cancer cells prompty kills the mouse, but first, the mouse makes fluid in the abdomen, also called ascites. 

Left Image: Lab Mice courtesy of wikimedia commons.

Chance Favors the Prepared Mind - Luis Pasteur

Then one day, a medical student injected a mouse and noticed something strange happened. What happened? Nothing.  The mouse didn't get cancer, and no fluid in the abdomen.  The first mouse that could kill cancer was discovered.

Spontaneous Regression of Cancer in the Mouse

Once identified as a "cancer killing" mouse, the little furry fellow was earmarked for study.  These were exciting times in the lab.  Researchers in the lab asked some urgent questions. Why didn't this mouse get cancer and ascites like all the others?  How was this mouse able to resist injected cancer cells? What was the mechanism for the rejection of the cancer cells?

Over the next 3 years, research studies showed these mice are immune to cancer, a trait innate to this SR/CR strain.  Their immunity to cancer was genetically determined.  These mice have an immune system that could fight cancer by sending immune cells, the leukocytes to attack and kill the cancer cells, just as any other microbial invader. These mice were dubbed SR/CR mice for Spontaneous Regression/Complete Resistant (to Cancer).(2)

Saving All the Other Mice From Cancer

What about the other normal mice? They had no immunity and promptly died of cancer.
Could these normal mice be saved by infusing the white cells, the lymphocytes,  from the SR/CR mice ?  More experiments quickly confirmed this was true, cancer resistance could be transferred to normal mice transfused with white blood cells from SR/CR mice.(3)  In addition, the protective SR/CR white cells could be stockpiled in cold storage, infused weeks later, and still retain activity.(4)

Human Mice - Spontaneous Regression of Cancer

What about us humans?  Do we have a similar immunity to cancer, with some humans able to resist cancer?  Yes, and this is called spontaneous regression  (remission) of cancer, which has been reported for virtually all cancers many times in the medical literature.  Spontaneous regression can be seen most commonly in neuroblastoma, renal cell carcinoma, malignant melanoma and lymphomas/leukemias (see Papac RJ and Chodorowski Z)(5)(6)

Sir William Osler, a legendary doctor reported 14 cases of breast cancer spontaneous remission.   I have seen a documented case of spontaneous regression of breast cancer.(8)  A study by Dr Gilbert Welch concluded that small breast cancers may spontaneously regress.  Gina Kolata wrote a New York Times piece about it.  

Adoptive Immunotherapy - A Promising New Cancer Treatment

The mouse model showed cancer resistance can be tranferred by white blood cells called T lymphocytes.  How about humans?  Steven A Rosenberg MD PhD has work in humans showing great promise.  As Chief of Surgery at the National Cancer Institute, Dr. Rosenberg has developed a cancer treatment using immunotherapy with T lymphocytes  infused into cancer patients.  His results have been remarkable.(7)  Dr Rosenberg's treatment uses a cancer patient’s own T lymphocytes which have innate anti-tumor activity, the lymphocytes are activated and cloned in a test tube, and then reinfused into the cancer patient.  This method is currently the most effective treatment for patients with metastatic melanoma producing tumor regressions in 50% of patients. See Rosenberg's case images below showing tumor regression (7).

Figure 2 from article: Examples of objective tumor regressions in patients receiving adoptive cell transfer of autologous anti-tumor lymphocytes following a lymphodepleting preparative regimen In each case the pretreatment scans and photos are shown on the left and the post-treatment on the right.

Left panel (a) A 45-year-old male with metastatic melanoma to the liver (upper) and right adrenal gland (middle) who was refractory to prior treatment with high dose α interferon as well as high-dose interleukin 2 (IL2). He underwent a rapid regression of metastases and developed vitiligo (lower).

Right panel (b) A 55-year-old male with rapid tumour growth in the axilla as well as multiple brain metastases from metastatic melanoma that was refractory to prior treatment with high dose IL2 who underwent rapid regression of nodal and brain metastases.

What's in the Future?

Since Adoptive cell transfer is not a drug, and competes with conventional drug treatment (chemotherapy), the pharmaceutical industry might be hostile to the idea.
T Cell Immune therapy is highly personalized treatment, labour-intensive and requires laboratory expertise.  Each lymphocyte preparation is uniquely created for each patient and this makes it difficult to commercialize.   Where to get the anti-tumor T cells?  Blood banks have been providing stem cells for clinical studies, and might also serve as a source for anti-tumour T cells.

Driving Through the Rear View Mirror - Fever Therapy

One of the curious things about spontaneous regression of cancer is its association with high fever from bacterial infection such as erysipales.  This was reported by surgeons many years ago when they observed that some cancer patients had a remarkable  regression of the tumor mass if their clinical course was complicated by post-operative infection of some type leading to high fever and chills.  If the infection didn't kill them, these cancer patients did well, with a remarkable remission from their cancer.

One such emminent sugeon was Chief of Bone Surgery at the Memorial Sloan Kettering Hospital.  His name was William Coley, and he perfected this treatment of injecting bacterial toxins (Coley's Toxins) into cancer patients inducing high fever, stimulating the immune system and obtaining remarkable regression in many inoperable cases. After a long and successful period of use, Coley died , and his Coley's Toxin treatment was banished from Memorial in 1955.  In 1963, the Food and Drug Administration (FDA) refused to “grandfather” Coley’s toxins, as a pre-existing medicine, making it illegal in the US.

Coley's toxins probably activated the immune system to send immune cells called  T lymphocytes to the tumor and kill it.  Perhaps Dr Steven Rosenberg can look through the rear view mirror, and the example of Coley's toxins,  and drive the NIH into the next century with a cure for cancer. 

Is this the end of cancer? I hope so.

Links and References

(1) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC164507/
Proc Natl Acad Sci U S A. 2003 May 27; 100(11): 6682–6687.
Spontaneous regression of advanced cancer: Identification of a unique genetically determined, age-dependent trait in mice. Zheng Cui, Mark C. Willingham, Amy M. Hicks, Martha A. Alexander-Miller et al.

We have established and studied a colony of mice with a unique trait of host resistance to both ascites and solid cancers induced by transplantable cells. One dramatic manifestation of this trait is age-dependent spontaneous regression of advanced cancers. This powerful resistance segregates as a single-locus dominant trait, is independent of tumor burden, and is effective against cell lines from multiple types of cancer. During spontaneous regression or immediately after exposure, cancer cells provoke a massive infiltration of host leukocytes, which form aggregates and rosettes with tumor cells. The cytolytic destruction of cancer cells by innate leukocytes is rapid and specific without apparent damage to normal cells. The mice are healthy and cancer-free and have a normal life span. These observations suggest a previously unrecognized mechanism of immune surveillance, which may have potential for therapy or prevention of cancer. 

(2) http://www.cancerimmunity.org/v6p11/060911.htm
Cancer Immunity, Vol. 6, p. 11 (31 October 2006) Submitted: 28 March 2006. Resubmitted: 17 July 2006. Accepted: 28 September 2006. Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice.

Amy M. Hicks et al. The killing of cancer cells in SR/CR mice requires three distinct phases. First, the leukocytes must migrate to the site of cancer cells after sensing their presence. Second, they must recognize the unique properties of the cancer cell surface and make tight contact with it. Third, the effector mechanisms must finally be delivered to target cells. The difference between SR/CR and WT mice seems to lie in one of the first two phases. Upon challenge with cancer cells, WT mice lack leukocyte infiltration and rosette formation. Apparently, the mutation in SR/CR mice renders the leukocytes capable of sensing unique diffusible and surface signals from cancer cells, and of responding to the activation signals by migration and physical contact. Once the first two phases are accomplished, unleashing the pre-existing effector mechanisms for killing seems to ensue by default. Therefore, the mutated gene (or genes) likely determines whether leukocytes interpret the signals from cancer cells as inhibition, as in WT leukocytes, or as activation of migration and target recognition, as in SR/CR leukocytes. Identifying the mutated gene (or genes) will likely explain this unique resistance to cancer through immunity.

(3) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1458507/?tool=pubmed
Proc Natl Acad Sci U S A. 2006 May 16; 103(20): 7753–7758.  Immunology Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Amy M. Hicks et al.

(4) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749872/?tool=pubmed
BMC Cancer. 2009; 9: 328. Impact of sex, MHC, and age of recipients on the therapeutic effect of transferred leukocytes from cancer-resistant SR/CR mice
John R Stehle, Jr,1 Michael J Blanks,2 Gregory Riedlinger,1,3 Jung W Kim-Shapiro,1 Anne M Sanders,1 Jonathan M Adams,1 Mark C Willingham,1 and Zheng Cui1
1Department of Pathology, Wake Forest University School of Medicine Winston-Salem, North Carolina 27157, USA

Abstract Background
Spontaneous Regression/Complete Resistant (SR/CR) mice are resistant to cancer through a mechanism that is mediated entirely by leukocytes of innate immunity. Transfer of leukocytes from SR/CR mice can confer cancer resistance in wild-type (WT) recipients in both preventative and therapeutic settings. In the current studies, we investigated factors that may impact the efficacy and functionality of SR/CR donor leukocytes in recipients.

Spontaneous regression of cancer in Humans

(5)http://www.ncbi.nlm.nih.gov/pubmed/9891219
In Vivo. 1998 Nov-Dec;12(6):571-8.
Spontaneous regression of cancer: possible mechanisms. Papac RJ.
Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA.

Spontaneous regression of cancer is reported in virtually all types of human cancer, although the greatest number of cases are reported in patients with neuroblastoma, renal cell carcinoma, malignant melanoma and lymhomas/leukemias. Study of patients with these diseases has provided most of the data regarding mechanisms of spontaneous regression. Mechanisms proposed for spontaneous regression of human cancer include: immune mediation, tumor inhibition by growth factors and/or cytokines, induction of differentiation, hormonal mediation, elimination of a carcinogen, tumor necrosis and/or angiogenesis inhibition, psychologic factors, apoptosis and epigenetic mechanisms. Clinical observations and laboratory studies support these concepts to a variable extent. The induction of spontaneous regression may involve multiple mechanisms in some cases although the end result is likely to be either differentiation or cell death. Elucidation of the process of spontaneous regression offers the possibility of improved methods of treating and preventing cancer.

(6) http://www.ncbi.nlm.nih.gov/pubmed/17724923
Przegl Lek. 2007;64(4-5):380-2.
[Spontaneous regression of cancer--review of cases from 1988 to 2006]
Chodorowski Z, Anand JS, Wiśniewski M, Madaliński M, Wierzba K, Wiśniewski J.
Katedra i Klinika Chorób Wewnetrznych, Geriatrii i Toksykologii Klinicznej, Akademii Medycznej w Gdańsku.

Spontaneous regression of malignant tumours is a rare and enigmatic phenomenon. We reviewed the cases of spontaneous regression of cancer in medical literature according to MEDLINE database in the period 1988-2006 and compared them with similar reviews from 1900-1987 period. The number of reported cases of spontaneous regression increased steadily in XX century, probably due to a rising interest in this problem and new possibilities of radiological and biopsy examinations. Spontaneous regression of malignancy was reported in almost all types of human cancer, although the greatest number of cases in years 1988-2006 were reported in patients with nephroblastoma, renal cell carcinoma, malignant melanoma, lymphoma. Elucidation of the process of spontaneous regression offers the possibility of improved methods of preventing andlor treating cancer.

Adoptive Cell Therapy ACT

(7) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553205/?tool=pubmed
Nat Rev Cancer. 2008 April; 8(4): 299–308.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg, Nicholas P. Restifo, James C. Yang, Richard A. Morgan, and Mark E. Dudley. Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA.

Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.

Figure 2
Examples of objective tumour regressions in patients receiving adoptive cell transfer of autologous anti-tumour lymphocytes following a lymphodepleting preparative regimen
In each case the pretreatment scans and photos are shown on the left and the post-treatment on the right. a | A 45-year-old male with metastatic melanoma to the liver (upper) and right adrenal gland (middle) who was refractory to prior treatment with high dose α interferon as well as high-dose interleukin 2 (IL2). He underwent a rapid regression of metastases and developed vitiligo (lower). b | A 55-year-old male with rapid tumour growth in the axilla as well as multiple brain metastases from metastatic melanoma that was refractory to prior treatment with high dose IL2 who underwent rapid regression of nodal and brain metastases.

The future of ACT

In contrast to common epithelial cancers, melanoma appears to be a tumour that naturally gives rise to anti-tumour T cells. However, other cancers are equally susceptible as the targets of reactive T cells. The susceptibility of melanoma to ACT provides optimism for the application of ACT to common epithelial cancers using TCR gene-modified lymphocytes.

A major problem with the application of ACT is that it is a highly personalized treatment and does not easily fit into current modes of oncological practice. The treatment is labour-intensive and requires laboratory expertise. In essence, a new reagent is created for each patient and this patient-specific nature of the treatment makes it difficult to commercialize. Pharmaceutical and biotechnology companies seek off-the-shelf drugs, easy to produce, vial and administer. From a regulatory standpoint, ACT might be more appropriately delivered as a service rather than as a ‘drug’. Blood banks have been instrumental in providing CD34+ haematopoietic stem cells for clinical studies and might be the ideal location for the generation of the anti-tumour T cells needed for ACT.

As modern science increasingly provides the physician with sophisticated information about the unique aspects of an individual cancer, changes in the modes of care delivery need to accommodate this. The ability to use this patient-specific information can lead to a new era of personalized medicine in which individual treatments, such as ACT, are devised for each patient.Studies of ACT have clearly demonstrated that the administration of highly avid anti-tumour T cells directed against a suitable target can mediate the regression of large, vascularized, metastatic cancers in humans and provide guiding principles as well as encouragement for the further development of immunotherapy for the treatment of patients with cancer.

(8)The Medical Aspects of Carcinoma of the Breast, with a Note on the Spontaneous Disappearance of Secondary Growths, OSLER W., American Medicine: April 6 1901; 17-19; 63-66. 

Coley's Toxins Fever Therapy

http://www.ralphmoss.com/html/coley.pdf
THE TREATMENT OF CANCER WITH COLEY’S TOXINS

http://bioinfo.tg.fh-giessen.de/cancer/hobohm-2005-bjc.pdf
British Journal of Cancer (2005) 92, 421 – 425 Fever therapy revisited
U Hobohm*,1 1University of Applied Sciences, Bioinformatics, Wiesenstrasse 14, D-35390 Giessen, Germany

http://findarticles.com/p/articles/mi_m0ISW/is_251/ai_n6112670/?tag=content;col1
Coley's Toxins—The First Century Townsend Letter for Doctors and Patients, June, 2004 by Helen Coley Nauts



Jeffrey Dach MD
4700 Sheridan Suite T
Hollywood Fl 33021
954-983-1443
http://www.jeffreydach.com/  
http://www.drdach.com/  
http://www.naturalmedicine101.com/  
http://www.truemedmd.com/  

Disclaimer click here: http://www.drdach.com/wst_page20.html  

The reader is advised to discuss the comments on these pages with his/her personal physicians and to only act upon the advice of his/her personal physician. Also note that concerning an answer which appears as an electronically posted question, I am NOT creating a physician -- patient relationship. Although identities will remain confidential as much as possible, as I can not control the media,
I can not take responsibility for any breaches of confidentiality that may occur.

Link to this article:
http://jeffreydach.com/2009/11/04/cancer-breakthrough-with-spontaneous-remission-by-jeffrey-dach-md.aspx

Copyright (c) 2009,2010 Jeffrey Dach MD All Rights Reserved. This article may be reproduced on the internet without permission, provided there is a link to this page and proper credit is given.

FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of issues of significance. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

 
Trackbacks
  • No trackbacks exist for this post.
Comments
Page: 1 of 1
  • 11-04-2009 Eddie wrote:


    Man, you have lately been on an impressive roll! I really appreciate the surge of lively and informative entries. Much to consider here.

    Is it just my imagination or have you lately been more attuned to cancer? Regardless, I'm happy to read some perspectives here that need a wider audience.

    In the realm of cancer, there is such a thirst for some really good information that can be understood by an intelligent layman that I encourage you to consider writing a short book on the subject. Your knowledge, insights, and ability to communicate could really halp a lot of people. Right now, most of the publications--both conventional and alternative--fall far short of what you could deliver insofar as some your articles here are indicative.
     
    Eddie

    _________________________________________________________
    disclaimer

    Reply to this
  • 11-11-2009 fred hoy wrote:
    cure my cancer song
    When I was young, it was flowing smooth, my pee came easily. Now that I am old it stops and
    starts, a degree of difficulty. I went to see my doctor, and he ordered me a test. They drew my
    blood, to know my score and plan for what is best. The lab report said my score was high,they
    needed to know much more. I asked my doc what did it mean when 16 was my score ? He said
    another test was needed ,he called it D.R.E. So he called a doctor of oncology ,to examine me.

    I went to see the doctor new and he explained to me.These fingers up your anus probe for a hard
    anomaly.If it proves out true then we must do some surgery. Radiation ,chemotherapy ,to make
    you cancer free. There is no guarantee of cure ,of that he is quite sure. He ordered me some drugs,
    to take each day to make me poor. I said I need a rest and decide whats best for me.So I began
    a search for a kinder ,gentler remedy.

    Along came Suzanne Sommers with her anti-cancer book. Each page I read and searched and
    had a very very good look. My biological markers , was dangerous at 16. I needed to bring it down,
    to less than all those teens. The cure to make you healthy, is more than exercise. A lot of fruit
    and veggies, with anti-oxident ties. Like the juice of mangosteen, and acai berry too. Along with
    acid reduction and alkalinity true.

    Its been a year since the truth I've known about the mystery. To extend my life and free myself
    from much anxiety. My prostate score declined and now stands less than 9.I give thanks to Suz
    Sommers for her excellent remedy. To those of you who are under stress and overwhelmed with
    fear. Empower you self with knowledge, then you'd need not shed a tear. You truly can be
    healthy, if you know what you must do. Use orthomolecular medicine,benefits to you.

    yipee yi yay yipee yi yo learn suz sommers cancer remedy.
    Reply to this
  • 06-23-2012 Jose Francisco Monjes Angeles wrote:
    Charles Starnes at AMGEN in California15 (DID A STUDY OF OUR IIMMUNEBOOSTER)

    THAT IS NOT TRUE. At about that time someone told the Minister of Health that the American Cancer Society had Coley's Toxins listed as a quack cancer treatment and treatment of cancer with Coley's Toxins was banned from use in Guatemala.

    Mr Martin is extremely knowledgeable about Coley toxins. He is retired and devoting his time and resources in helping cancer patients find alternatives that work. In his youth he witnessed a trial against a doctor who used unconventional therapies, and resolved then that some day, he would help turn the tide. He has been in contact with patients and doctors worldwide for a number of years now.

    Mr. Martin is the key contact for physicians who either want to learn to make their own toxins, or who want to secure a supply to try the substance with their patients. He will also help patients secure a supply of the toxins in Guatemala if the patient desires to self-administer the treatment.

    NOTE: WE NO LONGER DO IT. BUT WE TREAT PATIENTS WITH IT.

    Mr. Martin has been contacted lately by many patients who hear about him on Gary Null's show, and has spent a considerable amount of money and time responding to requests, without nary a word of response or thanks. Please contact him only if you are serious about pursuing the toxins and cannot find your information anywhere else.
    Guatemala

    Dr. Jose Francisco Monjes Angeles has been making the toxins and making them available to patients who want to come to Guatemala for treatment, and is also able to supply physicians around the world.

    WE WILL START: TREATING CANCER PATIENTS with our immunebooster (COLEY’S TOXIN IMPROVED) IN: A 24 Hour Hospital such as Hospital de Especialidades that is located on: 3ra. Calle "A" 14-67 Zona 4 Colonia Valle Del Sol, Mixco (I am an honorary partner) 24timezones.com/onlinemap/guatemala_mixco.php.

    CONTACT: José Francisco Monjes Angeles MEDICAL CONSULTANT RESEARCHER.

    E-mail: jmonjesa1@hotmail.co.uk jmonjesa1@yahoo.com.mx jmonjesa1@gmail.com


    WHAT WE ARE GOING TO DO IS Framingham_Heart_Study INVESTIGATION BUT OF CANCER PATIENTS.

    1. FIND GRANTS, CAPITAL. OR SEED MONEY FOR: INVESTIGATION OF THE IMMUNE BOOSTER (COLEY’S TOXIN IMPROVED) IN GUATEMALA (BUYING THE PROPERTIES FOR THE CANCER CLINIC). IMPROVE IN IT, TRAINING AND PRODUCING IT INDUSTRIALLY. CAN YOU HELP US?
    2. INCORPORATE OUR IMMUNEBOOSTER COLEY’S TOXIN IMPROVED) TO THE TREATMENT OF ADULT CANCER PATIENTS. CAN YOU HELP US?
    3. FIND BUYERS OF OUR IMMUNE BOOSTER (COLEY’S TOXIN IMPROVED) AND TRAINING. CAN YOU HELP US?
    4. CAN YOU HELP US? PROMOTING AND THE SELLING OF OUR IMMUNE-BOOSTER COLEY’S TOXIN IMPROVED).


    FIRST PHASE:
    1. PATENT THE ACTUAL FORMULA.
    SECOND PHASE:
    1. IMPROVEMENT OF THE FORMULA. GOAL >95%. 2. FORMULA DEVELOPMENT. 3. CLINICAL TRAIL PHASE III AND FOURTH. 4. PATENT. 5. PRODUCING IT INDUSTRIALLY.
    Reply to this

Page: 1 of 1
Leave a comment

 Name (required)

 Email (will not be published) (required)

 Website

Your comment is 0 characters limited to 3000 characters.